25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

PTIXW (Protagenic) Stock Analysis
Buy, Hold or Sell?

Let's analyze Protagenic together

I guess you are interested in Protagenic Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • πŸ“Š Fundamental Analysis (FA) – Protagenic’s Financial Insights
  • πŸ“ˆ Technical Analysis (TA) – Protagenic’s Price Targets

I'm going to help you getting a better view of Protagenic Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Protagenic Therapeutics Inc

I send you an email if I find something interesting about Protagenic Therapeutics Inc.

1. Quick Overview

1.1. Quick analysis of Protagenic (30 sec.)










1.2. What can you expect buying and holding a share of Protagenic? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$-0.17
Expected worth in 1 year
$-0.82
How sure are you?
20.0%

+ What do you gain per year?

Total Gains per Share
$-0.65
Return On Investment
-906.1%

For what price can you sell your share?

Current Price per Share
$0.07
Expected price per share
$0.04 - $0.3099
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Protagenic (5 min.)




Live pricePrice per Share (EOD)
$0.07
Intrinsic Value Per Share
$-130.81 - $191.89
Total Value Per Share
$-130.98 - $191.73

2.2. Growth of Protagenic (5 min.)




Is Protagenic growing?

Current yearPrevious yearGrowGrow %
How rich?-$88.3k$3.8m-$3.2m-530.7%

How much money is Protagenic making?

Current yearPrevious yearGrowGrow %
Making money-$1.3m-$1.5m$191.4k14.6%
Net Profit Margin907.8%-13,471.0%--

How much money comes from the company's main activities?

2.3. Financial Health of Protagenic (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#761 / 886

Most Revenue
#755 / 886

Most Profit
#256 / 886
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Protagenic?

Welcome investor! Protagenic's management wants to use your money to grow the business. In return you get a share of Protagenic.

First you should know what it really means to hold a share of Protagenic. And how you can make/lose money.

Speculation

The Price per Share of Protagenic is $0.0717. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Protagenic.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Protagenic, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $-0.17. Based on the TTM, the Book Value Change Per Share is $-0.16 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.25 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Protagenic.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-2.75-3,838.7%-0.87-1,218.4%-0.34-477.2%-0.46-642.9%-0.40-557.0%-1.82-2,531.5%
Usd Book Value Change Per Share-0.32-452.9%-0.16-226.5%-0.25-350.3%-0.18-254.8%0.004.2%1.742,429.5%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.32-452.9%-0.16-226.5%-0.25-350.3%-0.18-254.8%0.004.2%1.742,429.5%
Usd Price Per Share0.01-0.01-0.02-0.03-0.10-0.05-
Price to Earnings Ratio0.00--0.01--0.02--0.03--0.17--0.08-
Price-to-Total Gains Ratio-0.02--0.52--0.12--0.41--0.34--0.34-
Price to Book Ratio-0.04-0.02-0.03-0.03-0.08-0.04-
Price-to-Total Gains Ratio-0.02--0.52--0.12--0.41--0.34--0.34-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.0717
Number of shares13947
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.160.00
Usd Total Gains Per Share-0.160.00
Gains per Quarter (13947 shares)-2,265.1441.54
Gains per Year (13947 shares)-9,060.54166.16
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-9061-90710166156
20-18121-181320332322
30-27182-271930498488
40-36242-362540665654
50-45303-453150831820
60-54363-543760997986
70-63424-63437011631152
80-72484-72498013291318
90-81545-81559014951484
100-90605-90620016621650

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.040.00.00.0%12.081.02.012.6%
Book Value Change Per Share0.04.00.00.0%0.012.00.00.0%2.018.00.010.0%8.032.00.020.0%25.065.05.026.3%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%2.00.093.02.1%
Total Gains per Share0.04.00.00.0%0.012.00.00.0%2.018.00.010.0%8.032.00.020.0%25.065.05.026.3%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Protagenic Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.325-0.162-50%-0.251-23%-0.183-44%0.003-11001%1.742-119%
Book Value Per Share---0.1690.081-308%0.879-119%0.879-119%0.838-120%-7.677+4447%
Current Ratio--0.8621.673-48%5.184-83%6.259-86%7.104-88%4.774-82%
Debt To Asset Ratio--1.0890.639+71%0.194+460%0.319+242%1.066+2%2.197-50%
Debt To Equity Ratio---0.720-100%0.244-100%0.368-100%0.245-100%0.268-100%
Dividend Per Share----0%-0%-0%-0%-0%
Enterprise Value---200095.113329646.015-161%2082684.453-110%3024146.261-107%4991952.764-104%4991952.764-104%
Eps---2.752-0.874-68%-0.342-88%-0.461-83%-0.399-85%-1.815-34%
Ev To Ebitda Ratio--0.035-0.070+303%-0.654+1994%-1.076+3215%-1.489+4411%-1.489+4411%
Free Cash Flow Per Share---2.041-0.639-69%-0.293-86%-0.348-83%-0.269-87%-1.342-34%
Free Cash Flow To Equity Per Share---1.845-0.509-72%-0.293-84%-0.305-83%0.220-939%-0.119-94%
Gross Profit Margin--1.0001.007-1%1.0020%1.0030%1.0020%1.041-4%
Intrinsic Value_10Y_max--191.894----------
Intrinsic Value_10Y_min---130.811----------
Intrinsic Value_1Y_max--1.595----------
Intrinsic Value_1Y_min---6.727----------
Intrinsic Value_3Y_max--18.231----------
Intrinsic Value_3Y_min---25.858----------
Intrinsic Value_5Y_max--51.070----------
Intrinsic Value_5Y_min---51.031----------
Market Cap--3923.88827592.765-86%97033.090-96%115199.217-97%660120.785-99%330060.392-99%
Net Profit Margin---9.078-100%-134.7100%-41.8780%-24.9860%-12.4930%
Operating Margin---8.965-100%-134.7100%-41.9150%-24.8720%-12.4360%
Operating Ratio----9.7300%135.809-100%42.027-100%25.026-100%12.513-100%
Pb Ratio-0.425-856%-0.0440.022-304%0.032-239%0.027-263%0.075-159%0.038-218%
Pe Ratio-0.007-856%-0.001-0.007+889%-0.016+2304%-0.034+4897%-0.166+24297%-0.083+12098%
Price Per Share0.072+90%0.0080.007+3%0.022-66%0.027-72%0.103-93%0.051-85%
Price To Free Cash Flow Ratio-0.009-856%-0.001-0.018+1821%-0.016+1634%-0.038+4046%-0.320+34772%-0.160+17336%
Price To Total Gains Ratio-0.221-856%-0.023-0.517+2138%-0.124+435%-0.413+1689%-0.343+1385%-0.343+1385%
Quick Ratio--0.8111.367-41%7.307-89%10.634-92%10.879-93%6.932-88%
Return On Assets---1.457-0.943-35%-0.372-74%-0.468-68%-0.715-51%-0.794-45%
Return On Equity----1.1130%-0.4560%-0.5570%-0.3580%-0.3170%
Total Gains Per Share---0.325-0.162-50%-0.251-23%-0.183-44%0.003-11001%1.742-119%
Usd Book Value---88329.000609087.500-115%3841711.750-102%3897933.833-102%4085317.550-102%2436198.550-104%
Usd Book Value Change Per Share---0.325-0.162-50%-0.251-23%-0.183-44%0.003-11001%1.742-119%
Usd Book Value Per Share---0.1690.081-308%0.879-119%0.879-119%0.838-120%-7.677+4447%
Usd Dividend Per Share----0%-0%-0%-0%-0%
Usd Enterprise Value---200095.113329646.015-161%2082684.453-110%3024146.261-107%4991952.764-104%4991952.764-104%
Usd Eps---2.752-0.874-68%-0.342-88%-0.461-83%-0.399-85%-1.815-34%
Usd Free Cash Flow---1068017.000-906337.250-15%-1285225.500+20%-891928.250-16%-745834.550-30%-491617.120-54%
Usd Free Cash Flow Per Share---2.041-0.639-69%-0.293-86%-0.348-83%-0.269-87%-1.342-34%
Usd Free Cash Flow To Equity Per Share---1.845-0.509-72%-0.293-84%-0.305-83%0.220-939%-0.119-94%
Usd Market Cap--3923.88827592.765-86%97033.090-96%115199.217-97%660120.785-99%330060.392-99%
Usd Price Per Share0.072+90%0.0080.007+3%0.022-66%0.027-72%0.103-93%0.051-85%
Usd Profit---1440005.000-1310263.750-9%-1501673.750+4%-1177880.417-18%-1107185.550-23%-797160.500-45%
Usd Revenue----0%800.000-100%266.667-100%-23865.5000%-11932.7500%
Usd Total Gains Per Share---0.325-0.162-50%-0.251-23%-0.183-44%0.003-11001%1.742-119%
 EOD+4 -2MRQTTM+5 -29YOY+8 -263Y+6 -285Y+6 -2710Y+9 -24

3.3 Fundamental Score

Let's check the fundamental score of Protagenic Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.007
Price to Book Ratio (EOD)Between0-1-0.425
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.811
Current Ratio (MRQ)Greater than10.862
Debt to Asset Ratio (MRQ)Less than11.089
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.05-1.457
Total1/10 (10.0%)

3.4 Technical Score

Let's check the technical score of Protagenic Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5053.089
Ma 20Greater thanMa 500.049
Ma 50Greater thanMa 1000.022
Ma 100Greater thanMa 2000.016
OpenGreater thanClose0.080
Total4/5 (80.0%)

4. In-depth Analysis

4.1 About Protagenic Therapeutics Inc

Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. The company's lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc. is headquartered in New York, New York.

Fundamental data was last updated by Penke on 2025-05-21 13:39:05.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very efficient.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profitΒ Protagenic earns for each $1 of revenue.

  • Above 10% is considered healthy but always compareΒ Protagenic to theΒ Biotechnology industry mean.
  • A Net Profit Margin of 0.0%Β means thatΒ $0.00 for each $1Β in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Protagenic Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM907.8%-907.8%
TTM907.8%YOY-13,471.0%+14,378.8%
TTM907.8%5Y-2,498.6%+3,406.4%
5Y-2,498.6%10Y-1,249.3%-1,249.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--93.6%+93.6%
TTM907.8%-148.3%+1,056.1%
YOY-13,471.0%-196.4%-13,274.6%
3Y-4,187.8%-253.9%-3,933.9%
5Y-2,498.6%-344.9%-2,153.7%
10Y-1,249.3%-472.4%-776.9%
4.3.1.2. Return on Assets

Shows howΒ efficientΒ Protagenic is using its assets to generate profit.

  • Above 5% is considered healthyΒ but always compareΒ Protagenic to theΒ Biotechnology industry mean.
  • -145.7% Return on Assets means thatΒ Protagenic generatedΒ $-1.46 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Protagenic Therapeutics Inc:

  • The MRQ is -145.7%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -94.3%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-145.7%TTM-94.3%-51.4%
TTM-94.3%YOY-37.2%-57.1%
TTM-94.3%5Y-71.5%-22.8%
5Y-71.5%10Y-79.4%+7.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-145.7%-11.3%-134.4%
TTM-94.3%-11.3%-83.0%
YOY-37.2%-11.0%-26.2%
3Y-46.8%-11.7%-35.1%
5Y-71.5%-11.9%-59.6%
10Y-79.4%-13.8%-65.6%
4.3.1.3. Return on Equity

Shows how efficient Protagenic is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compareΒ Protagenic to theΒ Biotechnology industry mean.
  • 0.0% Return on Equity means Protagenic generated $0.00Β for eachΒ $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Protagenic Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-111.3%+111.3%
TTM-111.3%YOY-45.6%-65.7%
TTM-111.3%5Y-35.8%-75.5%
5Y-35.8%10Y-31.7%-4.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--13.0%+13.0%
TTM-111.3%-14.4%-96.9%
YOY-45.6%-14.4%-31.2%
3Y-55.7%-16.9%-38.8%
5Y-35.8%-17.4%-18.4%
10Y-31.7%-19.9%-11.8%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Protagenic Therapeutics Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

MeasuresΒ how efficient Protagenic is operatingΒ .

  • Measures how much profit Protagenic makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compareΒ Protagenic to theΒ Biotechnology industry mean.
  • An Operating Margin of 0.0%Β means the company generated $0.00 Β for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Protagenic Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM896.5%-896.5%
TTM896.5%YOY-13,471.0%+14,367.6%
TTM896.5%5Y-2,487.2%+3,383.7%
5Y-2,487.2%10Y-1,243.6%-1,243.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--201.1%+201.1%
TTM896.5%-255.4%+1,151.9%
YOY-13,471.0%-209.2%-13,261.8%
3Y-4,191.5%-219.9%-3,971.6%
5Y-2,487.2%-342.8%-2,144.4%
10Y-1,243.6%-444.3%-799.3%
4.3.2.2. Operating Ratio

Measures how efficient Protagenic is keepingΒ operating costsΒ low.

  • Below 1 is considered healthy (always compare toΒ Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Protagenic Therapeutics Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-9.730+9.730
TTM-9.730YOY135.809-145.539
TTM-9.7305Y25.026-34.756
5Y25.02610Y12.513+12.513
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.092-2.092
TTM-9.7302.709-12.439
YOY135.8093.049+132.760
3Y42.0273.652+38.375
5Y25.0264.724+20.302
10Y12.5136.335+6.178
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Protagenic Therapeutics Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Protagenic is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare toΒ Biotechnology industry mean).
  • A Current Ratio of 0.86Β means the company has $0.86 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Protagenic Therapeutics Inc:

  • The MRQ is 0.862. The company is just not able to pay all its short-term debts. -1
  • The TTM is 1.673. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ0.862TTM1.673-0.811
TTM1.673YOY5.184-3.512
TTM1.6735Y7.104-5.432
5Y7.10410Y4.774+2.330
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.8623.659-2.797
TTM1.6733.826-2.153
YOY5.1844.180+1.004
3Y6.2594.688+1.571
5Y7.1045.795+1.309
10Y4.7746.151-1.377
4.4.3.2. Quick Ratio

Measures if Protagenic is able to pay off Short-term Debt but only usingΒ theΒ most liquid assets.

  • Above 1 is considered healthy butΒ always compareΒ Protagenic to theΒ Biotechnology industry mean.
  • A Quick Ratio of 0.81Β means the company can pay off $0.81 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Protagenic Therapeutics Inc:

  • The MRQ is 0.811. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 1.367. The company is able to pay all its short-term debts with the most liquid assets. +1
Trends
Current periodCompared to+/- 
MRQ0.811TTM1.367-0.557
TTM1.367YOY7.307-5.940
TTM1.3675Y10.879-9.512
5Y10.87910Y6.932+3.947
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.8112.918-2.107
TTM1.3673.278-1.911
YOY7.3073.907+3.400
3Y10.6344.451+6.183
5Y10.8795.758+5.121
10Y6.9326.543+0.389
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Protagenic Therapeutics Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much %Β of ProtagenicΒ assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compareΒ Protagenic to Biotechnology industry mean.
  • A Debt to Asset Ratio of 1.09Β means that Protagenic assets areΒ financed with 108.9% credit (debt) and the remaining percentage (100% - 108.9%)Β is financed by its owners/shareholders.Β 

Let's take a look of the Debt to Asset Ratio trends of Protagenic Therapeutics Inc:

  • The MRQ is 1.089. The company is just not able to pay all its debts by selling its assets. -1
  • The TTM is 0.639. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ1.089TTM0.639+0.451
TTM0.639YOY0.194+0.444
TTM0.6395Y1.066-0.427
5Y1.06610Y2.197-1.132
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.0890.331+0.758
TTM0.6390.355+0.284
YOY0.1940.336-0.142
3Y0.3190.335-0.016
5Y1.0660.350+0.716
10Y2.1970.383+1.814
4.5.4.2. Debt to Equity Ratio

Measures ifΒ Protagenic is able toΒ pay off its debts by usingΒ shareholders equity.

  • Below 2 is considered healthy butΒ always compareΒ Protagenic to theΒ Biotechnology industry mean.
  • A Debt to Equity ratio of 0.0% means that company has $0.00 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Protagenic Therapeutics Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM0.720-0.720
TTM0.720YOY0.244+0.476
TTM0.7205Y0.245+0.475
5Y0.24510Y0.268-0.023
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.388-0.388
TTM0.7200.437+0.283
YOY0.2440.416-0.172
3Y0.3680.472-0.104
5Y0.2450.464-0.219
10Y0.2680.518-0.250
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

MeasuresΒ how much money you payΒ for each share forΒ every $1 in earnings Protagenic generates.

  • Above 15 is considered overpriced butΒ always compareΒ Protagenic to theΒ Biotechnology industry mean.
  • A PE ratio of 0.00 means the investor is paying $0.00Β for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Protagenic Therapeutics Inc:

  • The EOD is -0.007. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.001. Based on the earnings, the company is expensive. -2
  • The TTM is -0.007. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.007MRQ-0.001-0.006
MRQ-0.001TTM-0.007+0.006
TTM-0.007YOY-0.016+0.010
TTM-0.0075Y-0.166+0.159
5Y-0.16610Y-0.083-0.083
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.007-1.865+1.858
MRQ-0.001-2.022+2.021
TTM-0.007-2.536+2.529
YOY-0.016-3.632+3.616
3Y-0.034-3.711+3.677
5Y-0.166-6.083+5.917
10Y-0.083-6.649+6.566
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Protagenic Therapeutics Inc:

  • The EOD is -0.009. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -0.001. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -0.018. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.009MRQ-0.001-0.008
MRQ-0.001TTM-0.018+0.017
TTM-0.018YOY-0.016-0.002
TTM-0.0185Y-0.320+0.303
5Y-0.32010Y-0.160-0.160
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.009-2.575+2.566
MRQ-0.001-2.552+2.551
TTM-0.018-3.511+3.493
YOY-0.016-4.319+4.303
3Y-0.038-5.104+5.066
5Y-0.320-8.104+7.784
10Y-0.160-9.038+8.878
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price ofΒ Protagenic is to cheap or to expensiveΒ compared to its book value.

  • At or below 1 is considered healthyΒ (always compare to Biotechnology industry mean).
  • A PB ratio of -0.04 means the investor is paying $-0.04Β for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Protagenic Therapeutics Inc:

  • The EOD is -0.425. Based on the equity, the company is expensive. -2
  • The MRQ is -0.044. Based on the equity, the company is expensive. -2
  • The TTM is 0.022. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD-0.425MRQ-0.044-0.380
MRQ-0.044TTM0.022-0.066
TTM0.022YOY0.032-0.010
TTM0.0225Y0.075-0.053
5Y0.07510Y0.038+0.038
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.4251.885-2.310
MRQ-0.0441.889-1.933
TTM0.0222.194-2.172
YOY0.0322.499-2.467
3Y0.0272.668-2.641
5Y0.0753.652-3.577
10Y0.0384.290-4.252
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Protagenic Therapeutics Inc.

3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2024-03-312024-06-302024-09-302024-12-312025-03-31
Total Stockholder Equity 2,132-1,340793-747192941,013-1,101-88
Net Working Capital  2,022-1,327694-61633307940-1,089-149
Net Invested Capital  2,132-1,340793-747192941,013-1,101-88



5.2. Latest Balance Sheet

Balance Sheet of 2025-03-31. Currency in USD. All numbers in thousands.

Summary
Total Assets989
Total Liabilities1,077
Total Stockholder Equity-88
 As reported
Total Liabilities 1,077
Total Stockholder Equity+ -88
Total Assets = 989

Assets

Total Assets989
Total Current Assets928
Long-term Assets60
Total Current Assets
Cash And Cash Equivalents 873
Other Current Assets 55
Total Current Assets  (as reported)928
Total Current Assets  (calculated)928
+/-0
Long-term Assets
Property Plant Equipment 60
Long-term Assets  (as reported)60
Long-term Assets  (calculated)60
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities1,077
Long-term Liabilities0
Total Stockholder Equity-88
Total Current Liabilities
Accounts payable 165
Other Current Liabilities 1,077
Total Current Liabilities  (as reported)1,077
Total Current Liabilities  (calculated)1,242
+/- 165
Long-term Liabilities
Long-term Liabilities  (as reported)0
Long-term Liabilities  (calculated)0
+/-0
Total Stockholder Equity
Common Stock0
Retained Earnings -37,743
Accumulated Other Comprehensive Income -130
Other Stockholders Equity 37,785
Total Stockholder Equity (as reported)-88
Total Stockholder Equity (calculated)-88
+/-0
Other
Capital Stock0
Cash and Short Term Investments 873
Common Stock Shares Outstanding 523
Liabilities and Stockholders Equity 989
Net Debt -873
Net Invested Capital -88
Net Working Capital -149



5.3. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-312008-09-302008-06-302008-03-312007-12-312007-09-302007-06-302007-03-312006-09-302006-06-302006-03-312005-12-312005-09-302004-06-302003-06-302003-03-312002-12-312002-09-302002-03-312001-12-312001-09-302001-03-312000-12-312000-09-302000-03-311999-12-311999-09-301999-03-311998-12-311998-09-301998-03-311997-12-311997-09-301997-03-311996-12-311996-09-301996-06-301995-12-31
> Total Assets 
0
12,600
14,400
15,700
16,600
16,300
20,800
20,700
22,300
24,100
22,900
22,600
22,992
22,238
22,771
22,920
23,513
24,392
23,724
22,187
21,311
17,751
18,344
13,700
7,000
4
9
11
4
1
24,089
23,593
24,790
23,963
201,867
203,069
205,170
78,763
76,649
70,305
70,086
44,598
39,852
32,765
26,648
19,342
15,467
15,025
14,074
0
0
0
246
246
261
148
133
60
26
3,752
3,790
3,587
3,162
2,769
2,455
2,220
1,781
1,469
1,092
990
697
465
350
287
842
786
1,188
1,002
879
196
12,062
11,657
11,060
9,798
9,015
8,254
8,037
7,666
6,919
5,433
4,323
2,579
1,467
1,508
1,956
989
9891,9561,5081,4672,5794,3235,4336,9197,6668,0378,2549,0159,79811,06011,65712,0621968791,0021,1887868422873504656979901,0921,4691,7812,2202,4552,7693,1623,5873,7903,752266013314826124624600014,07415,02515,46719,34226,64832,76539,85244,59870,08670,30576,64978,763205,170203,069201,86723,96324,79023,59324,0891411947,00013,70018,34417,75121,31122,18723,72424,39223,51322,92022,77122,23822,99222,60022,90024,10022,30020,70020,80016,30016,60015,70014,40012,6000
   > Total Current Assets 
0
6,400
7,600
9,300
10,200
9,700
12,900
13,000
13,900
15,400
13,400
14,300
14,889
13,847
14,154
14,435
14,486
14,798
14,337
12,788
11,922
10,640
11,780
8,600
7,000
4
9
11
4
1
22,588
21,378
22,211
21,117
52,803
43,368
51,988
47,797
45,737
39,462
34,786
31,914
27,538
20,730
15,297
12,315
8,819
8,579
9,063
0
0
0
245
245
260
146
132
59
25
3,751
3,788
3,586
3,161
2,769
2,454
2,219
1,780
1,468
1,092
990
696
464
349
287
842
786
1,188
1,002
879
196
12,062
11,657
11,060
9,798
9,015
8,254
8,036
7,665
6,918
5,377
4,200
2,468
1,369
1,423
1,883
928
9281,8831,4231,3692,4684,2005,3776,9187,6658,0368,2549,0159,79811,06011,65712,0621968791,0021,1887868422873494646969901,0921,4681,7802,2192,4542,7693,1613,5863,7883,75125591321462602452450009,0638,5798,81912,31515,29720,73027,53831,91434,78639,46245,73747,79751,98843,36852,80321,11722,21121,37822,5881411947,0008,60011,78010,64011,92212,78814,33714,79814,48614,43514,15413,84714,88914,30013,40015,40013,90013,00012,9009,70010,2009,3007,6006,4000
       Cash And Cash Equivalents 
0
100
100
1,800
1,800
323
0
100
100
400
300
100
28
20
25
55
18
72
16
29
29
31
24
100
4,500
0
4
4
2
1
17,720
13,989
12,991
7,612
16,932
17,152
21,888
20,410
22,646
20,435
17,591
16,913
12,475
7,268
4,249
6,319
1,602
2,309
1,998
0
0
0
101
111
150
57
62
10
4
3,751
3,788
3,489
3,100
2,745
628
952
400
343
236
432
362
419
340
277
799
754
1,181
989
671
192
11,933
460
541
482
339
158
215
138
219
153
1,288
832
925
1,056
1,838
873
8731,8381,0569258321,28815321913821515833948254146011,9331926719891,1817547992773404193624322363434009526282,7453,1003,4893,7883,75141062571501111010001,9982,3091,6026,3194,2497,26812,47516,91317,59120,43522,64620,41021,88817,15216,9327,61212,99113,98917,720124404,500100243129291672185525202810030040010010003231,8001,8001001000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,838
13,047
0
3,950
4,245
243
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,826
1,152
1,286
1,083
850
494
250
0
0
0
0
0
0
0
0
0
0
10,395
9,830
9,303
8,530
7,994
7,764
7,512
5,823
5,119
2,768
1,592
0
0
0
0
00001,5922,7685,1195,8237,5127,7647,9948,5309,3039,83010,39500000000002504948501,0831,2861,1521,82600000000000000000000000002434,2453,950013,0472,838000000000000000000000000000000000
       Net Receivables 
0
2,400
3,200
2,800
3,500
3,700
4,000
5,300
6,000
6,000
5,700
6,100
6,603
5,568
6,294
6,058
6,450
5,954
5,693
4,619
4,384
2,646
3,865
2,900
2,200
4
4
6
0
0
3,627
4,839
6,268
9,111
18,856
22,269
20,321
19,456
18,001
14,330
14,168
12,358
13,151
12,504
10,170
5,431
5,648
4,477
5,378
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000000000000000000000000005,3784,4775,6485,43110,17012,50413,15112,35814,16814,33018,00119,45620,32122,26918,8569,1116,2684,8393,627006442,2002,9003,8652,6464,3844,6195,6935,9546,4506,0586,2945,5686,6036,1005,7006,0006,0005,3004,0003,7003,5002,8003,2002,4000
       Other Current Assets 
0
400
200
500
400
900
1,500
1,200
1,200
1,600
200
1,000
1,015
919
1,066
1,079
1,027
1,030
1,025
954
981
989
924
200
0
0
0
0
3
3
1,241
2,550
2,952
1,556
3,968
3,947
5,829
3,686
4,847
4,697
3,027
2,643
1,912
958
878
565
1,569
1,793
1,687
0
0
0
144
134
110
89
70
49
21
0
0
97
60
24
0
115
95
42
6
64
83
45
10
10
43
32
6
13
208
4
129
802
0
13
146
102
57
14
875
104
0
44
444
367
44
55
5544367444440104875145710214613080212942081363243101045836464295115024609700214970891101341440001,6871,7931,5695658789581,9122,6433,0274,6974,8473,6865,8293,9473,9681,5562,9522,5501,2413300002009249899819541,0251,0301,0271,0791,0669191,0151,0002001,6001,2001,2001,5009004005002004000
   > Long-term Assets 
0
6,200
6,800
6,400
6,400
6,600
7,900
7,700
8,400
8,700
9,500
8,300
8,103
8,391
8,617
8,485
9,027
9,594
9,387
9,399
9,389
7,111
6,564
5,100
0
0
0
0
0
0
1,501
2,215
2,579
2,846
149,064
159,701
153,182
30,966
30,912
30,843
35,300
12,684
12,314
12,035
11,351
7,027
6,648
6,446
5,011
0
0
0
1
1
1
2
1
1
1
2
1
1
1
0
1
1
1
1
1
1
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2
2
2
56
123
111
98
86
73
60
607386981111235622200000000000000111111110111211121110005,0116,4466,6487,02711,35112,03512,31412,68435,30030,84330,91230,966153,182159,701149,0642,8462,5792,2151,5010000005,1006,5647,1119,3899,3999,3879,5949,0278,4858,6178,3918,1038,3009,5008,7008,4007,7007,9006,6006,4006,4006,8006,2000
       Property Plant Equipment 
0
2,900
3,100
3,100
3,200
300
300
4,500
200
4,400
4,500
200
230
247
225
227
222
270
248
222
204
176
150
3,100
0
0
0
0
0
0
865
859
836
860
3,104
3,815
4,286
3,525
3,500
3,320
3,646
3,553
3,466
3,309
3,172
2,692
2,463
2,406
2,484
0
0
0
1
1
1
2
1
1
1
2
1
1
1
0
1
1
1
1
1
1
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2
2
2
56
123
111
98
86
73
60
607386981111235622200000000000000111111110111211121110002,4842,4062,4632,6923,1723,3093,4663,5533,6463,3203,5003,5254,2863,8153,1048608368598650000003,1001501762042222482702222272252472302004,5004,4002004,5003003003,2003,1003,1002,9000
       Goodwill 
0
3,200
3,200
0
0
3,055
0
0
3,336
0
0
3,126
3,020
2,966
2,859
2,805
2,752
2,648
2,597
2,547
2,440
0
0
0
0
0
0
0
0
0
0
0
0
0
97,980
101,373
100,852
11,075
11,981
12,096
12,096
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
404
0
0
0
404
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000000404000404000000000000000000000012,09612,09611,98111,075100,852101,37397,98000000000000002,4402,5472,5972,6482,7522,8052,8592,9663,0203,126003,336003,055003,2003,2000
       Intangible Assets 
0
0
0
3,200
3,100
3,000
3,000
2,900
3,300
3,200
3,200
3,100
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
460
1,208
904
599
41,298
45,903
44,044
12,508
11,117
10,426
12,850
7,253
7,080
6,907
6,733
3,083
2,973
2,887
1,380
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000000000000000000000000001,3802,8872,9733,0836,7336,9077,0807,25312,85010,42611,11712,50844,04445,90341,2985999041,2084600000000000000000003,1003,2003,2003,3002,9003,0003,0003,1003,200000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
> Total Liabilities 
0
5,500
7,400
2,100
3,100
2,800
7,200
6,800
8,000
9,800
8,800
8,800
10,048
9,082
8,999
9,061
9,633
10,677
10,221
8,865
8,913
8,319
9,150
8,800
4,200
146
163
173
176
28
4,937
4,583
7,171
7,098
36,562
37,018
40,636
24,114
23,954
19,050
20,345
19,251
17,564
14,697
11,975
11,170
10,538
16,139
19,725
0
0
0
316
435
589
602
704
767
892
736
603
648
685
593
578
537
562
504
533
667
908
827
729
651
1,477
1,372
1,934
2,023
2,029
2,179
1,264
1,287
1,118
1,079
756
872
1,120
1,252
1,505
1,280
655
446
675
789
943
1,077
1,0779437896754466551,2801,5051,2521,1208727561,0791,1181,2871,2642,1792,0292,0231,9341,3721,47765172982790866753350456253757859368564860373689276770460258943531600019,72516,13910,53811,17011,97514,69717,56419,25120,34519,05023,95424,11440,63637,01836,5627,0987,1714,5834,937281761731631464,2008,8009,1508,3198,9138,86510,22110,6779,6339,0618,9999,08210,0488,8008,8009,8008,0006,8007,2002,8003,1002,1007,4005,5000
   > Total Current Liabilities 
0
5,000
5,700
2,000
3,100
2,800
7,200
6,900
8,100
9,800
8,800
8,800
9,384
8,518
8,635
8,797
9,633
10,677
10,221
8,865
8,913
8,319
9,150
8,800
400
146
163
173
176
28
4,848
4,516
7,127
7,076
22,750
17,805
25,718
24,114
23,954
19,050
20,345
16,566
14,941
12,070
9,334
10,263
9,625
15,233
18,822
0
0
0
141
435
589
602
189
767
892
736
603
648
685
593
578
537
562
504
533
667
908
827
729
651
1,197
824
800
712
655
651
603
724
800
784
463
553
1,120
1,252
1,505
1,280
655
446
675
789
943
1,077
1,0779437896754466551,2801,5051,2521,1205534637848007246036516557128008241,19765172982790866753350456253757859368564860373689276718960258943514100018,82215,2339,62510,2639,33412,07014,94116,56620,34519,05023,95424,11425,71817,80522,7507,0767,1274,5164,848281761731631464008,8009,1508,3198,9138,86510,22110,6779,6338,7978,6358,5189,3848,8008,8009,8008,1006,9007,2002,8003,1002,0005,7005,0000
       Short-term Debt 
0
0
0
0
0
300
3,400
4,400
4,600
4,800
5,700
5,600
5,585
4,998
4,343
5,156
6,144
5,623
5,660
4,986
5,222
4,161
5,183
4,000
0
95
138
163
163
163
669
89
89
99
588
0
1,794
1,858
1,881
0
0
0
0
0
0
0
0
3,202
4,020
0
0
0
0
265
415
415
0
565
665
73
73
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
441
0
186
0
0
344
369
394
420
0
0
0
0
0
0
000000420394369344001860441000000000000000000007373665565041541526500004,0203,202000000001,8811,8581,79405889989896691631631631389504,0005,1834,1615,2224,9865,6605,6236,1445,1564,3434,9985,5855,6005,7004,8004,6004,4003,40030000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
344
369
394
420
0
0
0
0
0
0
00000042039436934400000000000000000000000000000000000000000000000000000000000000000000000000000000000000
       Accounts payable 
0
0
0
1,800
2,900
2,300
3,600
2,400
3,400
4,800
3,100
3,000
0
0
0
0
0
0
0
0
0
0
0
0
0
50
20
2
2
28
2,370
2,147
5,417
3,257
10,764
4,322
7,993
7,194
10,598
7,008
6,956
6,257
5,074
4,522
4,264
4,470
3,221
2,787
5,231
0
0
0
138
164
164
172
168
174
192
52
8
21
0
5
30
14
0
0
7
41
10
47
57
65
36
63
84
110
142
234
185
274
0
279
334
139
670
175
158
244
114
109
93
109
103
165
1651031099310911424415817567013933427902741852341421108463366557471041700143050218521921741681721641641380005,2312,7873,2214,4704,2644,5225,0746,2576,9567,00810,5987,1947,9934,32210,7643,2575,4172,1472,3702822205000000000000003,0003,1004,8003,4002,4003,6002,3002,9001,800000
       Other Current Liabilities 
0
5,000
5,700
200
200
200
200
100
100
200
0
200
3,799
3,520
4,292
3,641
3,489
5,054
4,561
3,879
3,691
4,158
3,967
4,800
400
2
4
8
11
-28
1,809
2,280
1,379
3,269
10,789
13,483
13,251
13,941
9,862
9,895
10,683
9,584
9,015
7,548
5,070
5,519
5,697
8,627
9,029
0
0
0
3
6
10
15
21
28
35
571
575
626
685
588
549
523
562
504
526
626
898
780
672
586
1,161
761
716
602
513
417
418
451
0
504
129
414
106
708
953
617
0
337
581
681
840
1,077
1,077840681581337061795370810641412950404514184175136027167611,1615866727808986265265045625235495886856265755713528211510630009,0298,6275,6975,5195,0707,5489,0159,58410,6839,8959,86213,94113,25113,48310,7893,2691,3792,2801,809-28118424004,8003,9674,1583,6913,8794,5615,0543,4893,6414,2923,5203,79920002001001002002002002005,7005,0000
   > Long-term Liabilities 
0
500
1,700
100
2,900
2,600
7,000
6,800
8,000
9,600
8,800
8,600
664
564
364
264
6,144
5,623
5,660
4,986
5,222
4,161
5,183
4,000
3,800
144
158
166
0
28
89
67
44
22
13,812
19,213
14,918
9,204
14,092
9,155
9,662
2,685
2,623
2,627
2,641
907
913
906
903
0
0
0
175
429
579
587
515
739
857
0
10
21
0
0
0
0
0
0
118
41
52
36
48
36
279
548
1,134
1,311
1,374
1,528
661
562
318
295
293
319
1,014
1,014
0
0
0
0
0
0
0
0
000000001,0141,0143192932953185626611,5281,3741,3111,1345482793648365241118000000211008577395155875794291750009039069139072,6412,6272,6232,6859,6629,15514,0929,20414,91819,21313,812224467892801661581443,8004,0005,1834,1615,2224,9865,6605,6236,1442643645646648,6008,8009,6008,0006,8007,0002,6002,9001001,7005000
> Total Stockholder Equity
0
7,000
7,000
13,600
13,500
13,500
13,600
13,900
14,300
14,300
14,100
13,800
12,944
13,156
13,772
13,859
13,880
13,715
13,503
13,322
12,398
9,432
9,194
5,000
2,700
-142
-154
-163
-172
-27
18,997
18,875
17,328
16,582
165,051
165,844
164,343
54,389
52,695
51,255
49,741
25,347
22,288
18,068
14,673
8,172
4,929
-1,114
-5,651
0
0
0
-21
-133
-266
-385
-497
-628
-786
3,016
3,187
2,939
2,477
2,177
1,877
1,683
1,219
965
560
323
-211
-362
-379
-364
-634
-586
-746
-1,021
-1,150
-1,983
10,798
10,371
9,942
8,720
8,258
7,382
6,918
6,414
5,414
4,153
3,668
2,132
793
719
1,013
-88
-881,0137197932,1323,6684,1535,4146,4146,9187,3828,2588,7209,94210,37110,798-1,983-1,150-1,021-746-586-634-364-379-362-2113235609651,2191,6831,8772,1772,4772,9393,1873,016-786-628-497-385-266-133-21000-5,651-1,1144,9298,17214,67318,06822,28825,34749,74151,25552,69554,389164,343165,844165,05116,58217,32818,87518,997-27-172-163-154-1422,7005,0009,1949,43212,39813,32213,50313,71513,88013,85913,77213,15612,94413,80014,10014,30014,30013,90013,60013,50013,50013,6007,0007,0000
   Common Stock
0
0
0
0
0
35
0
0
35
0
0
35
35
35
35
35
35
35
35
35
35
35
35
0
0
287
287
287
287
750
118
120
121
120
225
228
230
230
230
231
236
236
236
236
236
70
70
70
70
0
0
0
0
0
0
0
1,000
0
0
0
0
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
2
2
0
2
2
2
0
0
0
0
0
0
0
0
1
0
0100000000222022111111111111111111100001,000000000070707070236236236236236231230230230228225120121120118750287287287287003535353535353535353535350035003500000
   Retained Earnings Total Equity000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
-300
-300
-200
-200
-200
-300
-300
-300
-600
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-38
-190
0
-2,581
-286
-312
-183
-89
-20
26
1
17
42
84
80
32
0
0
0
0
0
0
0
-1,000
0
0
-148
-171
-174
-182
-180
-174
-167
-168
-169
-165
-165
-171
-173
-173
-173
-172
-175
-174
-173
-172
-171
-171
-172
0
-399
-450
-615
-677
-629
-586
-618
0
-87
-130
-130
-130
-130
-130-130-130-130-870-618-586-629-677-615-450-3990-172-171-171-172-173-174-175-172-173-173-173-171-165-165-169-168-167-174-180-182-174-171-14800-1,00000000003280844217126-20-89-183-312-286-2,5810-190-38000000000000000000000-600-300-300-300-200-200-200-300-300000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
15,237
15,643
16,326
16,720
17,093
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000017,09316,72016,32615,64315,237000000000000000000000000000000000000000000000000000000000000000000000000000
   Treasury Stock000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
10,200
10,400
18,000
17,900
17,700
17,800
17,800
17,900
17,900
17,900
17,600
16,589
16,589
16,589
16,569
16,569
16,569
16,614
16,605
16,605
16,605
16,605
16,700
16,600
-287
-287
-287
0
-568
18,185
18,948
19,349
19,583
168,366
167,901
168,984
173,294
172,571
173,192
173,963
173,627
173,780
174,076
174,301
0
176,335
176,449
176,481
0
0
0
1,053
1,053
5,159
1,174
2,053
1,485
1,320
10,210
10,928
11,138
11,240
11,595
11,741
11,994
12,228
12,572
12,836
13,097
13,358
13,809
14,070
14,209
14,687
15,237
15,643
16,326
16,720
17,093
31,420
31,873
0
32,701
32,957
33,171
33,371
33,538
33,705
33,872
0
34,721
35,031
35,598
37,445
37,785
37,78537,44535,59835,03134,721033,87233,70533,53833,37133,17132,95732,701031,87331,42017,09316,72016,32615,64315,23714,68714,20914,07013,80913,35813,09712,83612,57212,22811,99411,74111,59511,24011,13810,92810,2101,3201,4852,0531,1745,1591,0531,053000176,481176,449176,3350174,301174,076173,780173,627173,963173,192172,571173,294168,984167,901168,36619,58319,34918,94818,185-5680-287-287-28716,60016,70016,60516,60516,60516,60516,61416,56916,56916,56916,58916,58916,58917,60017,90017,90017,90017,80017,80017,70017,90018,00010,40010,2000



5.4. Balance Sheets

Currency in USD. All numbers in thousands.




5.5. Cash Flows

Currency in USD. All numbers in thousands.




5.6. Income Statements

Currency in USD. All numbers in thousands.


5.7. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue0
Cost of Revenue-50
Gross Profit0-50
 
Operating Income (+$)
Gross Profit0
Operating Expense-5,701
Operating Income-5,701-5,701
 
Operating Expense (+$)
Research Development3,845
Selling General Administrative1,759
Selling And Marketing Expenses0
Operating Expense5,7015,604
 
Net Interest Income (+$)
Interest Income43
Interest Expense-0
Other Finance Cost-0
Net Interest Income43
 
Pretax Income (+$)
Operating Income-5,701
Net Interest Income43
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-5,525-5,877
EBIT - interestExpense = -5,525
-5,525
-5,525
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-5,525-5,525
Earnings Before Interest and Taxes (EBITDA)-5,475
 
After tax Income (+$)
Income Before Tax-5,525
Tax Provision-0
Net Income From Continuing Ops-5,525-5,525
Net Income-5,525
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net176-43
 

Technical Analysis of Protagenic
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Protagenic. The general trend of Protagenic is BULLISH with 85.7% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Protagenic's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (85.7%) Bearish trend (-85.7%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Protagenic Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

SupportΒ is a price level at which demand for an asset is strong enough to prevent the price from falling further.
ResistanceΒ is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Protagenic Therapeutics Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 0.2177 < 0.3 < 0.3099.

The bearish price targets are: 0.04 > 0.04 > 0.04.

Know someone who trades $PTIXW? Share this with them.πŸ‘‡

Protagenic Therapeutics Inc Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows theΒ moving averageΒ of the selected period.

  • Moving averages are laggingΒ trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Protagenic Therapeutics Inc. The current mas is .

The long score for the Moving Averages is 13/14.
The longshort score for the Moving Averages is 12/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Protagenic Therapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows theΒ momentumΒ of theΒ selected period based on two moving averages.

  • MACD is aΒ lagging momentumΒ indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Protagenic Therapeutics Inc. The current macd is 0.02746101.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Protagenic price going up in the near term. +2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Protagenic. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Protagenic price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Protagenic Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartProtagenic Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Protagenic Therapeutics Inc. The current adx is 46.58.

The long score for the Directional Movement Index (DMI) is 4/7.
The longshort score for the Directional Movement Index (DMI) is 4/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Protagenic shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bullish trend. The ADX is trending up, so the bullish trend is strengthening.
Protagenic Therapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • ShowsΒ the current trend.
  • ShowsΒ potential entry signals.
  • ShowsΒ Β potential exit signals.
  • Can be used to placeΒ trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Protagenic Therapeutics Inc. The current sar is 0.46540384.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Protagenic Therapeutics Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentumΒ indicator, meaning the signals are instant.
  • RangesΒ between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Protagenic Therapeutics Inc. The current rsi is 53.09. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 3/13.
The longshort score for the Relative Strength Index (RSI) is 2/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
  • Trending down: The RSI is trending down. -1
Protagenic Therapeutics Inc Daily Relative Strength Index (RSI) ChartProtagenic Therapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

ComparesΒ a certain price to multiple prices ranging over time.

  • LeadingΒ momentumΒ indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • RangesΒ between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Protagenic Therapeutics Inc. The current phase is Oversold in bull market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Protagenic price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Protagenic Therapeutics Inc Daily Stochastic Oscillator ChartProtagenic Therapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,Β the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Protagenic Therapeutics Inc. The current cci is 26.94.

Protagenic Therapeutics Inc Daily Commodity Channel Index (CCI) ChartProtagenic Therapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Protagenic Therapeutics Inc. The current cmo is 0.84592942.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Protagenic Therapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartProtagenic Therapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

Β Shows the current price relative to the highest high over the last 14 days.
Β 

  • Lagging momentum indicator
  • Ranging between 0 andΒ -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Protagenic Therapeutics Inc. The current willr is -86.08767236.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Protagenic Therapeutics Inc Daily Williams %R ChartProtagenic Therapeutics Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversoldΒ 

Score

Let's take a look at the Bollinger Bands of Protagenic Therapeutics Inc.

Protagenic Therapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Protagenic Therapeutics Inc. The current atr is 0.05503187.

Protagenic Therapeutics Inc Daily Average True Range (ATR) ChartProtagenic Therapeutics Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Β Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Protagenic Therapeutics Inc. The current obv is 4,154,292.

Protagenic Therapeutics Inc Daily On-Balance Volume (OBV) ChartProtagenic Therapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Protagenic Therapeutics Inc. The current mfi is 81.30.

The long score for the Money Flow Index (MFI) is 2/2.
The longshort score for the Money Flow Index (MFI) is 2/(-2 +2).

  • MFI > 50: +1
  • MFI > 80: +1
Protagenic Therapeutics Inc Daily Money Flow Index (MFI) ChartProtagenic Therapeutics Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Protagenic Therapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-09-26DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-07DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-11-25MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-11-26CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-11-27MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-29STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-12-02CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-12-04CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-12-05WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-12-11SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-12-18SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-12-20MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-12-23CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-12-24WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-12-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-30DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-28STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-01-29DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-02-27STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-04MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-03-05CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-06CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-03-07STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-10SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-11MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-03-13STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-28STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-31MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-02STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-04-03CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-04-04DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-04-07MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-04-08STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-10STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-11MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-04-14MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-15MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-22DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-23STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-04-24STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-04-29STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-04-30DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-05-05SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-05-06WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-05-08CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-12STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-15MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-05-19STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-05-20STOCH LONG EXITThe %K line crosses below the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-21ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-22RSI SHORT ENTRY LONG CLOSE70 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-05-23STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-28SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-05-29STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside

6.3. Candlestick Patterns

Protagenic Therapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Protagenic Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5053.089
Ma 20Greater thanMa 500.049
Ma 50Greater thanMa 1000.022
Ma 100Greater thanMa 2000.016
OpenGreater thanClose0.080
Total4/5 (80.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Protagenic with someone you think should read this too:
  • Are you bullish or bearish on Protagenic? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Protagenic? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Protagenic Therapeutics Inc

I send you an email if I find something interesting about Protagenic Therapeutics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Protagenic Therapeutics Inc.

Receive notifications about Protagenic Therapeutics Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.